2. Search Result
Search Result
Results for "

receptor for advanced glycation end products (RAGE)

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50682
    Azeliragon
    10+ Cited Publications

    TTP488; PF-04494700

    		 Amyloid-β Neurological Disease Cancer
    Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon
  • HY-147329
    RAGE 229

    		Transmembrane Glycoprotein Metabolic Disease
    RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1) .
    RAGE 229
  • HY-W585874
    Nε-(Carboxyethyl)lysine

    		EAAT Neurological Disease
    Nε-(Carboxyethyl)lysine is an advanced glycation end product (AGE). Nε-(Carboxyethyl)lysine causes cross-linking between proteins, affects the structure and function of proteins, and leads to protein denaturation. Nε-(Carboxyethyl)lysine binds to RAGE receptors, affects cell signaling, regulates processes such as inflammatory response, cell proliferation and apoptosis. Nε-(Carboxyethyl)lysine affects glutamate transporter, reduces glutamate uptake and S100B protein secretion, affects neurotransmission in the nervous system, and exhibits diabetic-related neurotoxicity .
    Nε-(Carboxyethyl)lysine
  • HY-176305S
    Neurofilament, U-15N

    		Isotope-Labeled Compounds Neurological Disease
    Neurofilament, U- 15N is the 15N-labeled Neurofilament.
    Neurofilament, U-15N
  • HY-50682A
    Azeliragon dihydrochloride

    TTP488 dihydrochloride; PF-04494700 dihydrochloride

    		 Amyloid-β Neurological Disease Cancer
    Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB) .
    Azeliragon dihydrochloride
  • HY-50682R
    Azeliragon (Standard)

    		Amyloid-β Neurological Disease Cancer
    Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: